Oculis (OCS) to Release Earnings on Wednesday

Oculis (NASDAQ:OCS - Get Free Report) is projected to release its Q1 2025 earnings data before the market opens on Wednesday, May 14th. Analysts expect Oculis to post earnings of ($0.50) per share and revenue of $0.22 million for the quarter.

Oculis (NASDAQ:OCS - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.77) earnings per share for the quarter, missing analysts' consensus estimates of ($0.50) by ($0.27). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%. The firm had revenue of $0.32 million during the quarter, compared to analysts' expectations of $0.22 million. On average, analysts expect Oculis to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Oculis Stock Performance

NASDAQ:OCS traded down $0.64 during midday trading on Monday, reaching $17.94. The stock had a trading volume of 17,133 shares, compared to its average volume of 43,391. The firm has a fifty day simple moving average of $18.03 and a two-hundred day simple moving average of $18.39. Oculis has a 12-month low of $10.79 and a 12-month high of $23.08. The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.01. The stock has a market cap of $783.30 million, a P/E ratio of -9.30 and a beta of 0.27.

Analysts Set New Price Targets

A number of research firms have commented on OCS. HC Wainwright raised their target price on Oculis from $29.00 to $32.00 and gave the company a "buy" rating in a report on Thursday, April 17th. Robert W. Baird raised their target price on Oculis from $37.00 to $41.00 and gave the company an "outperform" rating in a report on Thursday, March 13th. Finally, Chardan Capital raised their target price on Oculis from $28.00 to $33.00 and gave the company a "buy" rating in a report on Friday.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.